SU6668 is an ATP-competitive PDGFR, Flk-1/KDR and FGFR inhibitor. It presents little activity against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2. It does not inhibit EGFR. SU6668 inhibits proliferation of HUVEC and NIH3T3 cells in-vitro and induces >75% growth inhibition against a broad range of tumor types. SU6668 shows antiangiogenic, anti-inflammatory, antimetastatic and proapototic activity and is orally active.
Peptides & proteins
TSU-68, Orantinib, (Z)-3-(2,4-dimethyl-5-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid
1) Sun, L., et al. 1999. J Med Chem. 42(25): 5120-5130. PMID: 10602697; 2) Piirsoo, A., et al. 2014. Biochim Biophys Acta. 2014 Apr;1843(4):703-14. PMID: 24418624
-20°C. Keep away from direct sunlight.
12 months from receipt